1Sahz LB,Meropol NJ,Loehrer PJ Sr,et al.Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor[J].J Clin Oncol,2004,22 (6):1201-1208.
2Cunningham D,Humblet Y,Siena S,et al.Cetuximab monotherapy and cetuximab plus irinotecan-refractory metastatic colorectal cancer[J].N Engl J Med,2004,351 (12):337-345.
3Huang SM,Book JM,Harari PM.Epidermal growth factor receptor blockade with C225 modulates proliferation,apoptosis,and radiosensitivity in squamous cell carcinomas of the head and neck[J].Cancer Res,1999,59 (11):1935-1940.
5Lenz HJ,Van Cutsem E,Khambata-Ford S,et al.Multicenter phase Ⅱ and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan,oxaliplatin,and fluoropyrimidines[J].J Clin Oncol,2006,24 (8):4914-4921.
